Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–23. https://doi.org/10.1182/blood-2013-04-460121.

Article  PubMed  CAS  Google Scholar 

Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(Supplement):e419S – e496. https://doi.org/10.1378/chest.11-2301.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–8. https://doi.org/10.1182/blood-2002-01-0108.

Article  PubMed  CAS  Google Scholar 

Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314:677–86. https://doi.org/10.1001/jama.2015.9243.

Article  PubMed  CAS  Google Scholar 

Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53. https://doi.org/10.1056/NEJMoa025313.

Article  PubMed  CAS  Google Scholar 

Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452–66. https://doi.org/10.1016/S1470-2045(16)30369-2.

Article  PubMed  CAS  Google Scholar 

Kahn SR, Springmann V, Schulman S, Martineau J, Stewart JA, Komari N, et al. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The recovery study. Thromb Haemost. 2012;108:493–8. https://doi.org/10.1160/TH12-03-0169.

Article  PubMed  CAS  Google Scholar 

Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol. 2008;52:865–8. https://doi.org/10.1016/j.jacc.2008.05.042.

Article  PubMed  Google Scholar 

Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543–603. https://doi.org/10.1093/eurheartj/ehz405.

Article  PubMed  Google Scholar 

Papakonstantinou PE, Tsioufis C, Konstantinidis D, Iliakis P, Leontsinis I, Tousoulis D. Anticoagulation in deep venous thrombosis: current trends in the era of non-vitamin K antagonists oral anticoagulants. Curr Pharm Des. 2020;26:2692–702. https://doi.org/10.2174/1381612826666200420150517.

Article  PubMed  CAS  Google Scholar 

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808. https://doi.org/10.1056/NEJMoa1302507.

Article  PubMed  CAS  Google Scholar 

Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15. https://doi.org/10.1056/NEJMoa1306638.

Article  CAS  Google Scholar 

Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral Rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. https://doi.org/10.1186/1477-9560-11-21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72. https://doi.org/10.1161/CIRCULATIONAHA.113.004450.

Article  PubMed  CAS  Google Scholar 

Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease. version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw JNCCN. 2021;19:1181–201. https://doi.org/10.6004/jnccn.2021.0047.

Article  PubMed  Google Scholar 

Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost. 2020;4:550–61. https://doi.org/10.1002/rth2.12359.

Article  PubMed  PubMed Central  Google Scholar 

Mulder FI, Bosch FTM, Young AM, Marshall A, McBane RD, Zemla TJ, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020;136:1433–41. https://doi.org/10.1182/blood.2020005819.

Article  PubMed  Google Scholar 

Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015;147:475–83. https://doi.org/10.1378/chest.14-0402.

Article  PubMed  Google Scholar 

Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6:CD006650. https://doi.org/10.1002/14651858.CD006650.pub5.

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clin Res Ed). 2021;372:n71. https://doi.org/10.1136/bmj.n71.

Article  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed). 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Article  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. https://doi.org/10.1016/0197-2456(86)90046-2.

Article  PubMed  CAS  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed). 2003;327:557–60. https://doi.org/10.1136/bmj.327.7414.557.

Article  Google Scholar 

Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142. https://doi.org/10.1002/14651858.ED000142.

Article  PubMed  Google Scholar 

Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (Clin Res Ed). 2011;343:d4002. https://doi.org/10.1136/bmj.d4002.

Article  Google Scholar 

Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64–75. https://doi.org/10.1016/j.jclinepi.2007.03.013.

Article  PubMed  Google Scholar 

Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187–91. https://doi.org/10.1111/jth.13153.

Article  PubMed  CAS  Google Scholar 

Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599–607. https://doi.org/10.1056/NEJMoa1915103.

Article  PubMed  CAS  Google Scholar 

Kim JH, Yoo C, Seo S, Jeong JH, Ryoo BY, Kim KP, et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers (Basel). 2022;14(3):559. https://doi.org/10.3390/cancers14030559.

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18:411–21. https://doi.org/10.1111/jth.14662.